Just read the RNS in detail and noticed "The £1m original investment by NetScientific in September enabled the execution of a complex deal, while the use of EMV Capital's investment network enabled the completion of the deal through further advised investment into Martlet Capital - enabling the return of much of the original investment to NSCI's balance sheet. " A very judicious investment strategy - the bod really make each £ work hard - plus we have an interest in 50+ technology assets - could do with a bit more info on this bit. I may drop them a line to seek elaboration - after my booster jab today.
Solid step forward in NSCI strategy. Looks like the right time in the right place:
Paul Bailey, the managing director of Martlet Capital, said Martlet was delighted to have the continued support of NetScientific.
From Proactive note:
“The European technology sector is booming and as reported in The Times recently, Britain is leading the way in tech investment with Cambridge being chosen as the unicorn capital of Europe. Early-stage investment levels are now on a par with the US for the first time and with the transatlantic links that NetScientific can offer Martlet's portfolio companies then we are in a great position to nurture founders, invest at seed stage, provide scale-up capital and talent management expertise to these amazing technology companies,” Bailey said.
I see some questioning management abilities - of which companies? We have over 20 managements being a holding company. Just the flagships: Proaxis - they get the full rights for an high end antibody test from Astra Zeneca in return for post sale royalties when 99% of Aimers would have to pay for such a product development ( prob by a placing)
Then they attract multiple grants from different organisations over the years - this year over £1m which goes along way to pay for product commercialisation - again see above.
Glyco has received $8.3m in grants over 10 years from various sources. And are savvy enough to tie up the Chinese market with a major pharmaceutical by a bi-lateral royalty/ shareholder agreement where many big companies fail to make inroads
Then check PDS catalysts due Q4/ Q1 2022
Looks to me that these managements are more on the case than most .
Afraid that’s totally wrong. RSP all over the place today on such small vol = in play
Thursday 500k sell at 25. Friday 21.5. Of course no buy quote for the same . Volume? Reckon there’s a few “phantom “ trades ( within seconds) trying to spook the 21 buyers last month to fool off . Guess but classic modus operandi to unwinkle even the more sophisticated to ……………..
RE: Email received today from Walbrook (ORPH PR co.)2 Dec 2021 21:17
Haven’t you soon the moronic trading in the last 6 months. Everywhere? There’s too many stupid peeps aka furlough kiddies - no idea why at a DCF is - have you ?
RE: Email received today from Walbrook (ORPH PR co.)1 Dec 2021 17:55
I’m not blaming you. I am pointing out your stupidity. There are many good stocks with good management that have halved in value this year. Bored with this. Bye
RE: Email received today from Walbrook (ORPH PR co.)1 Dec 2021 17:42
If you can’t see the current trend in AIM stocks then defo go back to work - if anyone will employ you. And please don’t tell me your a successful multi millionaire businessman lol